Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Fluzoparib, and Nab-paclitaxel in HRR-mutated Her2-negative breast cancer
NCT05761470Phase 2Recruiting
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, fluzoparib in breast cancer. Started May 2022; status: recruiting.
02
Drugs
camrelizumabfluzoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05761470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05761470.